NCT01831856View on ClinicalTrials.gov

Efficacy and Safety Study of F373280

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 3, 2017

Study Completion Date

June 21, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

1g of F373280

Oral administration, one capsule each evening with dinner.

DRUG

Placebo

Oral administration, one capsule each evening with dinner.

Trial Locations (20)

1023

Budapest

1032

Budapest

1096

Budapest

1122

Budapest

Unknown

Karlovy Vary

Praha 5 - Motol

Augusta

Brescia

Foggia

Terni

Verona

Grodzisk Mazowiecki

Radom

Sandomierz

Barcelona

Madrid

Santiago de Compostela

Tarragona

128 08

Prague

03-242

Warsaw

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT01831856 - Efficacy and Safety Study of F373280 | Biotech Hunter | Biotech Hunter